Limited coverage drugs – risankizumab for plaque psoriasis
Last updated on February 21, 2025
Return to Special Authority drug list
|
Generic name |
risankizumab |
||
|---|---|---|---|
|
Strength |
75 mg/ 0.83 mL |
150 mg/mL |
|
|
Form |
pre-filled syringe (subcutaneous injection) |
pre-filled pen (subcutaneous injection) |
|
|
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form 5380, when a Special Authority request is submitted by a dermatologist |
First approval: 16 weeks Renewal: 1 year |
Practitioner exemptions
- None
Special notes
- PharmaCare coverage of risankizumab is limited to 150 mg every 12 weeks at maintenance dosing. 150 mg loading doses are covered at weeks 0, 4 and 16